What is Vilya?
Vilya operates at the intersection of advanced computing and molecular biology, specializing in the creation of a novel class of medicines. Co-founded by a team of distinguished scientists from the Institute of Protein Design, including David Baker, Ph.D., the company utilizes cutting-edge computational approaches to explore uncharted chemical space within cyclic peptides. This platform allows for the design of molecular structures that do not exist in nature, providing a unique competitive advantage in the pharmaceutical sector. By focusing on the fundamental architecture of disease, Vilya aims to transform the drug design process, ultimately striving to deliver curative solutions for conditions that have historically remained difficult to treat.
How much funding has Vilya raised?
Vilya has raised a total of $71M across 1 funding round:
Series A
$71M
Series A (2024): $71M with participation from NVentures, ARCH Venture Partners, Madrona Venture Group, and Menlo Ventures
Key Investors in Vilya
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Madrona Venture Group
Founded in 1995, Madrona Venture Group is a venture capitalist investment company focusing on early-stage technology companies, including consumer internet, commercial software, and services.
Menlo Ventures
Menlo Ventures is a Menlo Park-based venture capital firm that invests in early and growth-stage technology companies across sectors such as enterprise software, consumer internet, fintech, infrastructure, and frontier tech.
What's next for Vilya?
Following this major strategic investment, Vilya is expected to scale its operational capacity and expand its pipeline of therapeutic candidates. The infusion of capital will likely be directed toward enhancing its computational infrastructure and accelerating the transition of its lead programs from the design phase into preclinical validation. As the company matures, it will focus on establishing key partnerships and refining its proprietary technology to ensure the scalability of its cyclic peptide platform. The strategic backing from top-tier venture firms provides not only the necessary financial runway but also the industry expertise required to navigate the complex regulatory and commercial pathways inherent in the biotechnology sector. Future milestones will likely center on demonstrating the clinical efficacy of its computationally designed molecules, marking a significant step forward in the evolution of precision medicine.
See full Vilya company page
